COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 494.7 | 4 | 0045-0401 | 830.60 | 401.78 | 210 | 53.94 | 0.907 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 438.8 | 4 | 0046-0420 | 198.06 | 419.82 | 219 | 57.46 | 0.834 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 423.8 | 4 | 0047-0424 | 944.84 | 423.39 | 270 | 62.77 | 0.861 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 413.9 | 4 | 0048-0440 | 392.04 | 441.07 | 265 | 65.84 | 0.768 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 642.9 | 4 | 0049-0447 | 554.05 | 446.96 | 215 | 56.18 | 0.856 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 528.4 | 4 | 0050-0446 | 249.81 | 446.92 | 191 | 53.11 | 0.851 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 379.2 | 4 | 0051-0477 | 904.87 | 477.53 | 234 | 57.70 | 0.883 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 479.9 | 4 | 0052-0487 | 80.59 | 487.68 | 262 | 62.77 | 0.836 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 457.3 | 4 | 0053-0502 | 230.11 | 501.89 | 197 | 53.46 | 0.866 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 3236.8 | 4 | 0054-0517 | 391.63 | 517.07 | 253 | 75.60 | 0.556 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 495.5 | 4 | 0055-0521 | 120.17 | 521.56 | 214 | 55.36 | 0.878 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 517.7 | 4 | 0056-0523 | 287.43 | 523.01 | 270 | 63.60 | 0.839 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 465.9 | 4 | 0057-0530 | 144.08 | 530.84 | 219 | 55.46 | 0.895 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 530.3 | 4 | 0058-0560 | 596.96 | 558.50 | 392 | 91.74 | 0.585 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 588.5 | 4 | 0059-0564 | 877.39 | 564.54 | 192 | 51.11 | 0.924 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 1840.9 | 4 | 0060-0577 | 810.69 | 577.11 | 389 | 74.43 | 0.882 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 421.2 | 4 | 0061-0591 | 113.98 | 591.55 | 247 | 59.94 | 0.864 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 401.9 | 4 | 0062-0606 | 659.17 | 606.68 | 297 | 78.57 | 0.605 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 559.0 | 4 | 0063-0617 | 452.28 | 617.65 | 211 | 56.77 | 0.823 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 521.8 | 4 | 0064-0621 | 193.27 | 621.27 | 221 | 60.43 | 0.761 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 481.6 | 4 | 0065-0637 | 190.91 | 637.47 | 228 | 60.18 | 0.791 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 475.6 | 4 | 0066-0644 | 397.00 | 643.71 | 282 | 63.36 | 0.883 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 541.2 | 4 | 0067-0653 | 92.97 | 652.55 | 189 | 56.53 | 0.743 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 704.3 | 4 | 0068-0654 | 106.20 | 654.06 | 160 | 50.04 | 0.803 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 430.3 | 4 | 0069-0663 | 678.63 | 663.18 | 247 | 64.43 | 0.748 |